ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $2.95 billion. The enterprise value is $3.03 billion.
| Market Cap | 2.95B |
| Enterprise Value | 3.03B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 221.85 million shares outstanding. The number of shares has decreased by -1.28% in one year.
| Current Share Class | 221.85M |
| Shares Outstanding | 221.85M |
| Shares Change (YoY) | -1.28% |
| Shares Change (QoQ) | -1.96% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 85.80% |
| Float | 205.22M |
Valuation Ratios
The trailing PE ratio is 17.24 and the forward PE ratio is 16.31.
| PE Ratio | 17.24 |
| Forward PE | 16.31 |
| PS Ratio | 5.70 |
| Forward PS | 5.05 |
| PB Ratio | 6.78 |
| P/TBV Ratio | 6.81 |
| P/FCF Ratio | 22.27 |
| P/OCF Ratio | 21.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.62, with an EV/FCF ratio of 22.86.
| EV / Earnings | 16.65 |
| EV / Sales | 5.85 |
| EV / EBITDA | 12.62 |
| EV / EBIT | 13.02 |
| EV / FCF | 22.86 |
Financial Position
The company has a current ratio of 6.04, with a Debt / Equity ratio of 0.46.
| Current Ratio | 6.04 |
| Quick Ratio | 3.08 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 0.84 |
| Debt / FCF | 1.53 |
| Interest Coverage | 22.04 |
Financial Efficiency
Return on equity (ROE) is 41.95% and return on invested capital (ROIC) is 36.54%.
| Return on Equity (ROE) | 41.95% |
| Return on Assets (ROA) | 22.41% |
| Return on Invested Capital (ROIC) | 36.54% |
| Return on Capital Employed (ROCE) | 36.60% |
| Weighted Average Cost of Capital (WACC) | 7.62% |
| Revenue Per Employee | $802,400 |
| Profits Per Employee | $281,937 |
| Employee Count | 647 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.71 |
Taxes
In the past 12 months, ADMA Biologics has paid $52.15 million in taxes.
| Income Tax | 52.15M |
| Effective Tax Rate | 22.23% |
Stock Price Statistics
The stock price has decreased by -16.93% in the last 52 weeks. The beta is 0.66, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -16.93% |
| 50-Day Moving Average | 10.98 |
| 200-Day Moving Average | 10.64 |
| Relative Strength Index (RSI) | 63.32 |
| Average Volume (20 Days) | 4,140,211 |
Short Selling Information
The latest short interest is 18.04 million, so 8.13% of the outstanding shares have been sold short.
| Short Interest | 18.04M |
| Short Previous Month | 19.53M |
| Short % of Shares Out | 8.13% |
| Short % of Float | 8.79% |
| Short Ratio (days to cover) | 6.47 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $519.15 million and earned $182.41 million in profits. Earnings per share was $0.77.
| Revenue | 519.15M |
| Gross Profit | 355.76M |
| Operating Income | 233.25M |
| Pretax Income | 234.56M |
| Net Income | 182.41M |
| EBITDA | 240.70M |
| EBIT | 233.25M |
| Earnings Per Share (EPS) | $0.77 |
Balance Sheet
The company has $124.56 million in cash and $202.80 million in debt, with a net cash position of -$78.25 million or -$0.35 per share.
| Cash & Cash Equivalents | 124.56M |
| Total Debt | 202.80M |
| Net Cash | -78.25M |
| Net Cash Per Share | -$0.35 |
| Equity (Book Value) | 438.51M |
| Book Value Per Share | 1.97 |
| Working Capital | 480.59M |
Cash Flow
In the last 12 months, operating cash flow was $140.80 million and capital expenditures -$7.89 million, giving a free cash flow of $132.91 million.
| Operating Cash Flow | 140.80M |
| Capital Expenditures | -7.89M |
| Depreciation & Amortization | 7.46M |
| Net Borrowing | 122.66M |
| Free Cash Flow | 132.91M |
| FCF Per Share | $0.60 |
Margins
Gross margin is 68.53%, with operating and profit margins of 44.93% and 35.14%.
| Gross Margin | 68.53% |
| Operating Margin | 44.93% |
| Pretax Margin | 45.18% |
| Profit Margin | 35.14% |
| EBITDA Margin | 46.36% |
| EBIT Margin | 44.93% |
| FCF Margin | 25.60% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.28% |
| Shareholder Yield | 1.28% |
| Earnings Yield | 5.80% |
| FCF Yield | 4.49% |
Analyst Forecast
The average price target for ADMA Biologics is $18.00, which is 35.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.00 |
| Price Target Difference | 35.44% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 11.03% |
| EPS Growth Forecast (3Y) | 22.37% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 8.61 and a Piotroski F-Score of 4.
| Altman Z-Score | 8.61 |
| Piotroski F-Score | 4 |